...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug news & perspectives >The role of erythropoietin in neuroprotection: Therapeutic perspectives.
【24h】

The role of erythropoietin in neuroprotection: Therapeutic perspectives.

机译：促红细胞生成素在神经保护中的作用：治疗观点。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nervous system diseases are very complex conditions comprising a large variety of local and systemic responses. Several therapeutic agents interfering with all or in part the biochemical steps that ultimately cause neuronal death have been demonstrated to be neuroprotective in preclinical models. However, all the agents so far investigated have inexorably failed in the phase III trials carried out. A large body of evidence suggests that the hormone erythropoietin (EPO), besides its well-known hematopoietic action, exerts beneficial effects in the central nervous system. EPO's effect has been assessed in several experimental models of brain and spinal cord injury thus becoming a serious candidate for neuroprotection. The use of EPO as neuroprotectant raises several questions. Besides dosage and therapeutic time window, the safety of recombinant EPO administration in the setting of nervous system diseases takes priority over all other questions. Although recombinant EPO seems to be potentially safe at the neuroprotective proved doses, cardiovascular or cerebrovascular events can occur as a result of its bone marrow stimulating activities. The successful trial using EPO in patients with ischemic stroke and the large body of experimental evidence encourages intensive evaluation of this cytokine to support safe and larger clinical trials in the near future. (c) 2007 Prous Science. All rights reserved.
机译：神经系统疾病是非常复杂的疾病，包括多种局部和全身反应。在临床前模型中，已证明几种干扰全部或部分最终导致神经元死亡的生化步骤的治疗剂具有神经保护作用。但是，到目前为止，所有进行调查的药物在进行的III期试验中都不可避免地失败了。大量证据表明，促红细胞生成素（EPO）激素除其众所周知的造血作用外，还对中枢神经系统产生有益作用。 EPO的作用已在几种脑和脊髓损伤的实验模型中进行了评估，因此成为神经保护的重要候选者。使用EPO作为神经保护剂引起了几个问题。除了剂量和治疗时间窗外，在发生神经系统疾病的情况下，重组EPO给药的安全性比所有其他问题都重要。尽管重组EPO在神经保护证明剂量下似乎是潜在安全的，但由于其骨髓刺激活性，可能发生心血管或脑血管事件。在患有缺血性中风和大量实验证据的患者中成功使用EPO进行试验，鼓励对该细胞因子进行深入评估，以支持不久的将来进行安全且大型的临床试验。 （c）2007 Prous科学。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号